- Eisai Co. Ltd.
- MGI Pharma Inc.
- Celgene Corp.
- Pharmion Corp.
- Biogen Inc.
- Elan Corp. PLC
- Genentech Inc.
- Johnson & Johnson
- Trubion Pharmaceuticals Inc.
- Abbott Laboratories Inc.
- Infinity Pharmaceuticals Inc.
- MedImmune LLC
- AstraZeneca PLC
- Ionis Pharmaceuticals Inc.
- Genzyme Corp.
- Dynogen Pharmaceuticals Inc.
- Eisai buys MGI Pharma
- Celgene buys Pharmion for $2.6bn in cash and stock
- Biogen, Elan to co-develop and sell Antegren; deal terminated
- Genentech licenses Idec B-cell lymphoma treatment
- AHP, Elan develop Alzheimer's vaccine; concluded
- Trubion, Wyeth co-develop CD20-targeted drugs; deal terminated
- Genentech helps Abbott develop and market two candidates
- Infinity, MedImmune, AZ restructure Hedgehog deal
- AstraZeneca buys MedImmune for $15.6bn
- Discovery Partners and Infinity merge
- Genzyme and Isis enter $1.2bn CV collaboration
- Idec buys Biogen for $6.84bn in stock
- Dynogen to go public in reverse merger with Apex; withdrawn
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.